Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease

Zenthuja Sivalingam; Sanne Bøjet Larsen; Erik Lerkevang Grove; Anne-Mette Hvas; Steen Dalby Kristensen; Nils Erik Magnusson

doi:10.1515/cclm-2017-0120

Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease

Zenthuja Sivalingam, Sanne Bøjet Larsen, Erik Lerkevang Grove, Anne-Mette Hvas, Steen Dalby Kristensen, Nils Erik Magnusson

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.

Original language	English
Journal	Clinical Chemistry and Laboratory Medicine
Volume	56
Issue	1
Pages (from-to)	5-18
Number of pages	14
ISSN	1434-6621
DOIs	https://doi.org/10.1515/cclm-2017-0120 https://doi.org/10.1515/cclm-2017-0120
Publication status	Published - 2017

Keywords

Journal Article
Review

Access to Document

Cite this

@article{bc43c51f469b40fbb2859229961045d0,

title = "Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease",

abstract = "Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.",

keywords = "Journal Article, Review",

author = "Zenthuja Sivalingam and Larsen, {Sanne B{\o}jet} and Grove, {Erik Lerkevang} and Anne-Mette Hvas and Kristensen, {Steen Dalby} and Magnusson, {Nils Erik}",

year = "2017",

doi = "10.1515/cclm-2017-0120",

language = "English",

volume = "56",

pages = "5--18",

journal = "Clinical Chemistry and Laboratory Medicine",

issn = "1434-6621",

publisher = "Walterde Gruyter GmbH",

number = "1",

}

Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease. / Sivalingam, Zenthuja; Larsen, Sanne Bøjet; Grove, Erik Lerkevang et al.
In: Clinical Chemistry and Laboratory Medicine, Vol. 56, No. 1, 2017, p. 5-18.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

TY - JOUR

T1 - Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease

AU - Sivalingam, Zenthuja

AU - Larsen, Sanne Bøjet

AU - Grove, Erik Lerkevang

AU - Hvas, Anne-Mette

AU - Kristensen, Steen Dalby

AU - Magnusson, Nils Erik

PY - 2017

Y1 - 2017

N2 - Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.

AB - Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.

KW - Journal Article

KW - Review

U2 - 10.1515/cclm-2017-0120

DO - 10.1515/cclm-2017-0120

M3 - Review

C2 - 28672731

SN - 1434-6621

VL - 56

SP - 5

EP - 18

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

IS - 1

ER -

Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this